Is a complete SPRY research report available?

No complete published report is available for ARS Pharmaceuticals, Inc. (SPRY) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

ARS Pharmaceuticals, Inc. (SPRY)

NASDAQ: SPRY · USD

$5.63

-0.20 (-3.4%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-31 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first SPRY analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	559.1M
Revenue (ttm)	99M
Net income (ttm)	-198M
EPS (ttm)	-$2.00
Shares out	99.3M
Volume	1,626,860
Beta	0.88
Price target	$26.8	+375.1%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 99M
Net income (ttm): -198M
EPS (ttm): -$2.00
Market cap: 559.1M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All SPRY indicators

Market & fundamental data

Available fields

210

Groups with data

Currency

USD

Showing 210 of 210 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001671858
Company name	ARS Pharmaceuticals, Inc.
Country	United States
Country code	US
Cusip	82835W108
Employees	159
Employees Change	-4%
Employees Change Percent	-2.45
Enterprise value	$528.3M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US82835W1080
Last refreshed	2026-07-31
Market cap	$559.1M
Market cap category	Small-Cap
Price	$5.63
Price currency	USD
Rev Per Employee	622,553.46x
Sector	Healthcare
Sector PE	45.51
Sector PE Fwd	24.23
Sic	2834
Symbol	SPRY
Website	https://ars-pharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-35.47%
EV Sales Forward	3.3x
EV/Sales	5.34x
FCF yield	-31.41%
P/B ratio	9.1x
P/S ratio	5.64x
PS Forward	3.49x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-204.49%
EBITDA Margin	-202.99%
Gross margin	59.41%
Gross Profit	$58.8M
Gross Profit Growth	-24.37%
Gross Profit Growth Q	207.08%
Net Income	$-198M
Net Income Growth Years	0%
Pretax Margin	-200.08%
Profit Margin	-200%
Profit Per Employee	$-1.2M
ROA	-41.15
Roa5y	-18.07
ROCE	-85.06
ROE	-136.4
Roe5y	-42.08
ROIC	-584

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-68.31%
Cagr3y	-7.44%
EPS Growth Years	0
Revenue Growth	1.92x
Revenue Growth Q	184.47x
Revenue Growth Quarters	1x
Revenue Growth Years	0x
Revenue Growth3 Y	427.86x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.32
Assets	$287.6M
Cash	$201M
Current Assets	$245.2M
Current Liabilities	$49.6M
Debt	$171.2M
Debt Equity	$2.79
Equity	$61.3M
Interest Coverage	-40.16
Liabilities	$226.3M
Long Term Assets	$42.3M
Long Term Liabilities	$176.7M
Net Cash	$29.8M
Net Cash By Market Cap	$5.34
Net Cash Growth	-85.57%
Net Debt Equity	$-0.49
Tangible Book Value	$47.1M
Tangible Book Value Per Share	$0.47
WACC	7.49

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	4.94
Inventory Turnover	5
Net Working Capital	$-5.3M
Quick ratio	4.64
Working Capital	$195.6M
Working Capital Turnover	$0.42

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-1.59%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-68.28%
200-day SMA	9.02
3Y total return	-20.7%
50-day SMA	8.18
50-day SMA vs 200-day SMA	50under200
All Time High	18.9
All Time High Change	-70.21%
All Time High Date	2025-06-27
All Time Low	2.55
All Time Low Change	120.78%
All Time Low Date	2023-09-20
ATR	0.51
Beta	0.88
Beta1y	1.78
Beta2y	1.38
Ch YTD	-51.67
High	5.85
High52	18.42
High52 Date	2025-07-30
High52ch	-69.43%
Low	5.48
Low52	5.35
Low52 Date	2026-07-29
Low52ch	5.23%
Ma50ch	-31.17%
Premarket Change Percent	-0.17
Premarket Price	$5.82
Premarket Volume	5,802
Price vs 200-day SMA	-37.55%
RSI	25.4
RSI Monthly	39.18
RSI Weekly	33.24
Sharpe ratio	-1.31x
Sortino ratio	-1.7
Total Return	-1.59%
Tr YTD	-51.67
Tr1m	-34.23%
Tr1w	-6.17%
Tr3m	-28.19%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	4
Analyst Count Top	1
Analyst Price Target Top	$30
Analyst Ratings	Strong Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-0.5
Earnings Revenue Estimate	31,690,800x
Earnings Revenue Estimate Growth	101.63x
Operating Income	$-202.4M
Operating margin	-204.5
Price target	$26.75
Price Target Change	$375
Price Target Change Top	$433

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	48,431,291%
Float Percent	48.77%
Net Borrowing	96,257,000
Shares Insiders	6.15%
Shares Institutions	58.03%
Shares Out	99,303,262
Shares Qo Q	0.27%
Shares Yo Y	1.59%
Short Float	46.81%
Short Ratio	11.35
Short Shares	22.83

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-199.5M
Adjusted OCF	-199,290,000
Average Volume	2,281,246.9x
Bv Per Share	0.62
CAPEX	$-248,000
Ch1m	-34.23
Ch1w	-6.17
Ch1y	-68.28
Ch3m	-28.19
Ch3y	-20.7
Ch6m	-44.91
Change	-3.43%
Change From Open	-2.93
Close	5.83
Days Gap	-0.51
Depreciation Amortization	1,484,000
Dollar Volume	9,159,221.8
Earnings Date	2026-08-07
Earnings Time	bmo
EBIT	$-202.4M
EBITDA	$-200.9M
EPS	$-2
F Score	1
FCF	$-175.3M
FCF EV Yield	-33.18x
FCF Per Share	$-1.77
Financing CF	104,032,000
Fiscal Year End	December
Founded	2,015
Income Tax	$-80,000
Investing CF	55,495,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-15
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-09
Ma150	8.9
Ma150ch	-36.73%
Ma20	7
Ma20ch	-19.59%
Net CF	-15,543,000
Next Earnings Date	2026-08-12
Open	5.8
Optionable	Yes
Position In Range	40.54
Post Close	5.63
Postmarket Change Percent	0.36
Postmarket Price	$5.65
Ppne	2,285,000
Pre Close	5.83
Price Date	2026-07-30
Ptbv Ratio	11.84
Relative Volume	0.71x
Revenue	98,986,000x
SBC By Revenue	24.47x
Share Based Comp	24,220,000
Tax By Revenue	-0.08x
Tr6m	-44.91%
Us State	California
Volume	1,626,860
Z Score	0.25

ARS Pharmaceuticals, Inc. (SPRY)

Coverage state: Market snapshot only — no published research

Generate the first SPRY analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · SPRY

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All SPRY indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on SPRY

Frequently asked questions